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Essentials
• Vessel stenosis due to large thrombus formation increases local shear 1-2 orders of magnitude.
• High shear at stenotic sites was exploited to trigger eptifibatide release from nanocapsules.
• Local delivery of eptifibatide prevented vessel occlusion without increased tail bleeding times.
• Local nanocapsule delivery of eptifibatide may be safer than systemic antiplatelet therapies.
Summary. Background: Myocardial infarction and stroke remain the leading causes of mortality and morbidity. The major limitation of current antiplatelet therapy is that the effective concentrations are limited because of bleeding complications. Targeted delivery of antiplatelet drug to sites of thrombosis would overcome these limitations. Objectives: Here, we have exploited a key biomechanical feature specific to thrombosis, i.e. significantly increased blood shear stress resulting from a reduction in the lumen of the vessel, to achieve site-directed delivery of the clinically used antiplatelet agent eptifibatide by using shear-sensitive phosphatidylcholine (PC)-based nanocapsules. Methods: PC-based nanocapsules (2.8 9 10
12
) with high-dose encapsulated eptifibatide were introduced into microfluidic blood perfusion assays and into in vivo models of thrombosis and tail bleeding. Results: Shear-triggered nanocapsule delivery of eptifibatide inhibited in vitro thrombus formation selectively under stenotic and high shear flow conditions above a shear rate of 1000 s À1 while leaving thrombus formation under physiologic shear rates unaffected. Thrombosis was effectively prevented in in vivo models of vessel wall damage. Importantly, mice infused with shear-sensitive antiplatelet nanocapsules did not show prolonged bleeding times. Conclusions: Targeted delivery
Introduction
Superimposed thrombus formation at sites of atherosclerosis restricts the remaining lumen and increases local blood shear stresses to extreme values. Recent studies demonstrated that arterial thrombosis and vascular remodeling are strongly promoted by biomechanical forces, particularly pathologic shear stress [1] . In addition, we and others previously demonstrated that von Willebrand factor unfolding or activation [2, 3] and shear gradient-dependent platelet aggregation mechanisms [4] promote arterial thrombosis. Large thrombi create a local microenvironment with high shear stress that exacerbates thrombus growth. Current antiplatelet therapy is not tailored to respond to local prothrombotic effects of pathologic shear stress [5] . Furthermore, the systemic nature of antiplatelet therapy results in only limited drug concentrations at sites of thrombus formation but is directly associated with an increased bleeding risk, including fatal bleeds. Various targeting strategies have been explored to increase local drug concentrations at sites of thrombi. Recent studies have elegantly demonstrated the potential of targeting the fibrinolytic agent tissue-type plasminogen activator to blood clots by using glycoprotein (GP) IIbIIIa activation-specific single-chain antibodies [6] [7] [8] or shear-sensitive copolymers of lactic acid and glycolic acid, which act as a drug carrier that disaggregates at high shear stress to allow local binding to developed thrombi [9] . Therapeutics involving nanocapsules (NCs) have shown enormous promise for targeted delivery of drugs at disease sites, partly because of their high payload of drugs and the capability to functionalize their surface with adhesive ligands [10] . However, to date, the use of therapeutic NCs in the prevention or treatment of thrombosis or vascular remodeling has been limited [9] . One of the main reasons for the lack of translation of NCs to the clinic is that there are few platforms that can rapidly evaluate the biological behavior of antithrombotic NCs under in vitro conditions that can be correlated with their performance in vivo [11] . Traditional methods for evaluating the release of encapsulated contents from lipid NCs typically involve measurements of spectroscopic changes of the bulk sample when encapsulated compounds react with the external medium. These methods, although useful to evaluate stressors on NC stability and latency, are not functional assays that allow assessment of local drug release at desired locations such as sites of thrombus formation.
We developed microfluidic platelet function assays and employed animal thrombosis models to directly determine phosphatidylcholine (PC)-based NC delivery of the antiplatelet drug eptifibatide specifically at vessel segments harboring pathophysiologic shear stress. Drug release and shear sensitivity of the NCs could be controlled, and was measured by the degree of platelet aggregation inhibition. Localization of high concentrations of antiplatelet drugs to areas of high shear stress demonstrated effective antiplatelet action without prolonging tail bleeding times. This study demonstrates the feasibility and potential application of NC antiplatelet drug delivery to sites of thrombosis.
Materials and methods

NC preparation
NCs were prepared from PC (Avanti, Alabaster, AL, USA; 840051C), supplemented where indicated with 0.06 mol% ethoxylated fatty alcohol polyoxyethylene(10) stearyl ether (Brij76), with the thin-film rehydration method. Lipid in chloroform (16 lmol) was added to a flat-bottomed beaker and dried with nitrogen. Samples were left covered in a vacuum desiccator overnight to produce a dried multilamellar lipid film. Samples were rehydrated with 1 mL of phosphate-buffered saline (PBS) with the indicated antiplatelet drugs for 10 min at 55°C. Samples were subjected to six freeze-thaw cycles between liquid nitrogen and a 37°C water bath, to produce large unilamellar vesicles. Samples were then extruded 11 times through a polycarbonate membrane with 200-nm pores (Whatman Track-Etch membrane; GE Healthcare, Parramatta, Australia) at 55°C to produce vesicles with a diameter of~200 nm, as assessed by light scattering with a Zetasizer lV analyser (Malvern Instruments, Malvern, UK). Non-encapsulated drugs were removed by dialysis against PBS.
Microfluidic flow channels and blood perfusion
Polydimethylsiloxane channels were manufactured by use of an SU-8 master mold that was fabricated by standard photolithography methods, as previously described [3] . Wall shear rates of the input flow for the microchannels were calculated from volumetric flow rates by using the equation c = 6Q/wh 2 
Platelet aggregation
Platelet-rich plasma (PRP) was prepared from sodium citrate (3.2%) anticoagulated whole blood, collected from healthy donors, and used within 3 h. Platelet aggregation was assessed by light transmission aggregometry, and induced by ADP in the presence of either PBS, intact NCs, or 'shear-disrupted' NCs. Shear disruption of NCs was achieved by vortexing for 3 min and then sonicating for 3 min. ) loaded with PBS (PBS-NCs) or eptifibatide (E-NCs) at the indicated loading concentrations were infused intravenously as a 100-lL bolus into wild-type mice 5 min or 40 min prior to thrombus formation in the carotid artery induced by topical application (3 min) of 5% (w/v) ferric chloride. Occlusive thrombus formation leading to flow cessation in the carotid artery was monitored with a Doppler ultrasound probe (0.5VB; Transonic, Tokorozawa, Japan). Blood clearance: 2.8 9 10 12 NCs with 0.5 mol% NDB-PE were injected intravenously and counted in blood samples collected at the indicated time points. Counting was performed by the use of fluorescence microscopy in microfluidic channels as liposome density per field of view, and normalized against the density at time point 0. Organ distribution: after intravenous injection of 2.8 9 10
12 NCs containing trace amounts of [ 3 H]PC, mice were killed after 2 h. Tissue samples were homogenized in sterile water, and 3 H radioactivity was determined by liquid scintillation counting. Tissue radioactivity was normalized to sample weight.
Tail bleeding time
The hemostatic potential of mice was assessed by using the template tail bleeding time method. A longitudinal incision, 2 mm in depth and 4 mm in length, was made, starting 10 mm from the proximal side of the tail. Incisions were made over the superficial tail vein running along the left axis of the tail. NC solution (100 lL) was administered intravenously via the tail vein, 5 min prior to incision. Tail bleeding was monitored and dabbed with a Whatman filter paper for up to 20 min.
Pulmonary thrombus load model
Thrombi were induced by infusing a mixture of 5% (v/v) Innovin (recombinant tissue factor and synthetic phospholipids) and 10 lg mL À1 Cy7-labeled fibrinogen at 5 lL g À1 body weight via the tail vein. Mice were killed after 1 h, and perfused with saline. The fibrin(ogen) content was imaged in excised lungs with an Odyssey infrared Imager (Li-Cor, Lincoln, NE, USA) and analyzed for fluorescence surface area, relative to total lung area, with IMAGEJ.
Computational fluid dynamics
A finite volume scheme using OPENFOAM [12] was used to solve numerically the fluid flow equations (NavierStokes). The fluid medium was considered to be homogeneous with a constant density (998 kg m À3 ) and Newtonian viscosity, as blood can be approximated as a Newtonian fluid at middle and high strain rates. We used the analytic solution of the velocity profile for a Newtonian fluid in rectangular geometries, as described previously [13, 14] .
Statistical analysis
All data are expressed as mean AE standard error of the mean and were analyzed with one-way ANOVA followed by post hoc Bonferroni tests, unless otherwise indicated. P-values of < 0.05 were considered to be significant.
Results
Site-specific delivery of antiplatelet drugs to areas of vessel stenosis
The hemodynamic environment at sites of vessel stenosis, caused by near-occlusive thrombi, is intrinsically prothrombotic, owing to the generation of high blood shear rates. To test the efficacy of E-NCs in specifically inhibiting thrombus formation under stenotic flow conditions, we used our microfluidic stenosis model, in which thrombus formation is exacerbated in the stenosis apex and outlet zones [3] (Fig. 1A) . Perfusion of whole blood in the presence of E-NCs reduced thrombus formation exclusively in the stenotic section (8000 s À1 ), and had no effect on thrombus volume in the upstream areas of the channel, where shear rates were 1000 s À1 (Fig. 1B,C ). These data demonstrate the specificity of the drug delivery for areas of high shear stress at stenotic vessel segments. This effect of the E-NCs was not attributable to entrapment of the NCs in the platelet aggregates, as no stably adherent fluorescent NCs could be detected (Fig. 1Dii) , and all NCs passed the aggregates during blood perfusion (Fig. 1Diii) . The overall size distribution of the NCs, measured with dynamic light scattering, did not change after exposure to 10 passes through the stenosis channels at maximum flow rate generating~40 000 s À1 in the stenosis apex (Fig. S1 ).
To estimate the maximal level of eptifibatide release induced by application of shear stress, platelet aggregation was induced by 5 lM ADP in the presence of sheardisrupted E-NCs and compared with aggregation levels of PRP incubated with a range of eptifibatide concentrations. Intact E-NCs had a minimal inhibitory effect on platelet aggregation, whereas shear-disrupted E-NCs inhibited platelet aggregation (from 89.7% AE 1.1% to 24.7% AE 8.5%) (Fig. 1E ), equivalent to 361 nM free eptifibatide (Fig. 1F) . Similar results were obtained for PRP stimulated by 2.5 lM and 10 lM ADP (Fig. S2) . Taking into account the original loading concentration of eptifibatide inside the NCs (350 lM), the combined internal , platelet aggregation was reduced in the presence of E-NCs ( Fig. 2A,B) . The shear dependency of the inhibition indicates that potential passive eptifibatide leakage prior to perfusion is minimal and does not affect the capacity of the NCs. To assess the exact shear rate at which the NCs release their contents and inhibit thrombus formation, we designed and employed a tapering microfluidic channel to produce a gradual increase from 300 s À1 at the inlet to 3400 s À1 at the outlet, as determined by computational fluidic dynamics modeling (Fig. 2C) . The channel was coated with 50 lg mL
À1
collagen type I, and perfused with whole blood in the presence or absence of 1.23 mg mL À1 E-NCs (2.8 9 10 12 particles mL À1 ). Under control conditions, platelet aggregate size shear-dependently increased from~1000 s À1 onwards (Fig. 2D) . Consistent with the results in Fig. 2A , platelet aggregate sizes in the presence of 350 lM E-NCs were not statistically different from control up to 1000 s
. A statistical difference between PBS-NCs and E-NCs was reached at 2200 s À1 . NCs loaded with 2 mM eptifibatide significantly reduced platelet aggregate size from 1500 s À1 onwards (Fig. 2D) . These data demonstrate that release of encapsulated eptifibatide is shear rate-dependent and sufficient to limit platelet aggregate formation at high shear rates.
To directly visualize the behavior of the NCs during their travel through the stenotic segment in the microfluidic channels, we applied high-speed fluorescence microscopy. NCs were loaded with 20 lM 5(6)-carboxyfluorescein, perfused in PBS through the stenosis channels at 1000 s À1 input shear, and imaged at 20 000 frames s -1 .
Consistent with the light scattering results (Fig. S1 ), NCs did not show visible signs of rupture or disintegration in the stenotic sections during perfusion (Fig. S3A) . However, there was a relative increase in the fluorescence intensity of the NCs as they passed through the apex of the stenosis (Fig. S3A) . Importantly, the increase in NC fluorescence intensity in the apex of the stenosis was further increased when the NCs were perfused in a medium with higher viscosity: 50% (v/v) plasma in PBS and 100% plasma (Fig. S3B) . These data indirectly demonstrate that stenotic segments expose NCs to mechanical stressors that have viscosity (shear stress)-dependent effects on the NCs.
NC release of eptifibatide is shear-dependent
To verify that the release of antiplatelet drugs from the NCs was driven by a shear-dependent process, we partially destabilized the lipid bilayer of the NCs with the ethoxylated fatty alcohol Brij76. This detergent increases the permeability of the PC membrane, which aids shear-induced pore formation and consequent drug release [15, 16] . Citrate anticoagulated whole blood in the presence of 1.23 mg mL À1 E-NCs (2.8 9 10 12 particles mL À1 ) loaded with 350 lM eptifibatide and containing 0.06 mol% Brij76 was perfused over a matrix of collagen type I. Brij76 E-NCs did not affect total platelet surface area coverage at 500 s À1 . However, in contrast to E-NCs without detergent (Fig. 2) , the platelet surface area was significantly reduced at 1000 s À1 to the level of 1.4 lM free eptifibatide (Fig. 3A,B) . The incorporation of Brij76 reduced the shear threshold for drug release from > 1500 s À1 as shown in To further characterize the shear-dependent relationship between NC stability and inhibition of platelet aggregation, Brij76 concentrations were varied from 0 mol% to 0.12 mol% and tested at 500 s À1 and 1000 s
À1
. Progressive reduction of NC stability with increasing Brij76 concentrations led to a concomitant reduction in platelet aggregate formation at 1000 s À1 but not at 500 s À1 (Fig. 3C ). NC delivery of eptifibatide is shear-dependent above a threshold that can be modulated through partial destabilization of the lipid bilayer with Brij76.
Antiplatelet NCs prevent thrombotic occlusion in vivo
To demonstrate the antithrombotic efficacy of the shearsensitive antiplatelet NCs in vivo, we assessed the effects of E-NCs loaded with 350 lM eptifibatide that were administered intravenously into C57/Bl6 mice (100 lL at 12.3 mg mL
À1
, corresponding to 2.8 9 10 12 NCs) 5 min prior to ferric chloride-induced carotid artery injury. Infusion of 2.8 9 10
12 PBS-NCs resulted in similar occlusion times as obtained with PBS vehicle only (Fig. 4A) . To validate the shear sensitivity of the NCs, intact E-NCs with and without 0.06% Brij76 were introduced into the carotid artery injury model. The presence of 0.06% Brij76 resulted in a loss of efficacy of the NCs (Fig. 4B) , probably because of shear disruption of the NCs in the normal mouse circulation [17] . Stabilization of the NCs by removal of Brij76 rescued the antithrombotic capacity of the E-NCs (Fig. 4B,C) . Manual shear disruption of E-NCs prior to infusion resulted in a failure to maintain vessel patency, with blood flow decreasing to zero in 7-8 min, indicating that, when eptifibatide is released prior to infusion, the final systemic concentrations of the drug remain below effective doses for preventing vessel occlusion. Extending the time from injection to vessel injury from 5 min to 40 min resulted in a loss of E-NC efficacy (Fig. 4C) . Consistent with this, E-NCs showed biphasic clearance with a half-life of 10 min (Fig. 4D) . Two hours following injection, the majority of E-NCs were localized to the spleen and liver (Fig. 4E) . 
Antiplatelet NCs reduce pulmonary thrombus load
In mice, the venous circulation harbors, on average, approximately four-fold lower shear stress levels than the arterial circulation [17] ; however, as local shear stress levels during occlusive thrombus formation can increase up to 100-fold [18] , shear-sensitive NCs may also inhibit occlusive thrombus formation in the venous circulation, or reduce the impact of venous emboli in the high-shear vascular system of the lungs. Thus, we assessed the applicability of E-NCs for reducing thrombus formation originating in the venous circulation. In contrast to traditional pulmonary embolism models, in which preformed emboli are injected, we measured the extent of thrombus load in the lung induced by intravenous injection of Innovin (containing tissue factor, phospholipids, and calcium) in the tail vein in the presence of 2.8 9 10 12 circulating E-NCs loaded with 350 lM eptifibatide. Fluorescently labeled fibrin(ogen) was used to visualize and quantify emboli in the lungs. We first tested whether a single high dose of free eptifibatide injected at the clinical loading dose of 180 lg kg À1 prior to the administration of Innovin could reduce the total load of emboli in the lung.
Under control conditions, 12.5% AE 1.7% of the total lung surface area was occupied by fibrin(ogen)-rich structures (Fig. 5A) . A single dose of E-NCs reduced the fibrin(ogen) content in the lungs to 3.8% AE 0.4% (Fig. 5A,B) , which was similar to the fibrin(ogen) content following administration of 180 lg kg À1 free eptifibatide. Although no assessment can be made on the qualitative features of the fibrin-rich structures, the total burden of fibrin deposition in the lungs was reduced in the presence of E-NCs.
Antiplatelet NCs do not prolong tail bleeding time
To assess the hemostatic profile in the presence of E-NCs, tail bleeding times were monitored. A longitudinal incision was made over the left peripheral tail vein 1 cm from the proximal end of the tail, and time to cessation of bleeding was monitored. Injection of PBS-NCs resulted in a baseline tail bleeding time of 200 s, whereas injection of a clinical loading dose of free eptifibatide (180 lg kg À1 ) increased tail bleeding time to 800 s (Fig. 6 ). E-NCs (2. prior to injection did not increase tail vein bleeding time. These data demonstrate that, under these conditions, the presence of shear-sensitive antiplatelet NCs does not lead to sufficiently high systemic drug concentrations to interfere with normal hemostasis and thereby prolong tail bleeding time. 
Discussion
We previously demonstrated that stenotic sites are prothrombotic, particularly downstream of stenotic vessel segments, owing to large variations in shear stress [3, 4] . Although mechanical forces play a well-recognized role in arterial thrombosis [1, 3] , traditional antiplatelet therapies rely on chemical targeting of platelet adhesion receptors and intracellular activation pathways. The link between pathologic shear stress and exacerbated thrombus formation has justified recent developments of shear-sensitive nanotherapeutics [9, 15, 19] . However, strategies to site-specifically inhibit platelet adhesion by exploiting the shear stress at sites of occlusive thrombus formation have not been explored. The lack of suitable in vitro and in vivo thrombosis models has hampered the accurate assessment of targeted delivery of antiplatelet drugs. We have applied microfluidic and mouse thrombosis models to test the hypothesis that membrane pore formation [20] and the release of high-dose antiplatelet drugs from NCs occurs site-specifically when local shear rate levels increase because of a thrombus developing to near-occlusive dimensions. We encapsulated the antiplatelet agent eptifibatide (Integrilin) in shear-sensitive NCs composed of Egg PC. Eptifibatide binds reversibly to GPIIb-IIIa, and is only used in selected patients, typically those undergoing high-risk percutaneous coronary intervention (PCI), because of the associated risk of bleeding [21, 22] . Because of side effects of bleeding, the clinical use is restricted, and has become more so with the availability of oral P2Y 12 inhibitors [23] . We found that shear-sensitive antiplatelet NCs released eptifibatide sufficiently to limit platelet aggregate size and surface coverage in vitro, and prevented thrombotic occlusion in vivo under conditions in which blood shear rates reached pathologic levels. The absence of NCs inside a developing thrombus is consistent with other reports [24] , and excluded the possibility that they became trapped and subsequently released drugs in a shear-independent manner. Local shear rates of vessels constricted by thrombi can increase by one to two orders of magnitude [25] , indicating that shear-sensitive NCs could be effective in both the arterial and venous circulations. Indeed, thrombi formed in the venous circulation in the presence of antiplatelet NCs showed a lower thrombus load in the lung circulation. Although the mechanisms of venous thrombus formation are distinct from those of arterial (mural) thrombus formation, a key role for pathologic high shear in both models is likely [9] . Tail bleeding times, which represent a model for drug safety and an indication of hemostatic potential, not thrombotic potential, were normal in the presence of antiplatelet NCs. The mechanism by which antiplatelet NCs allow platelet plug formation during the tail bleeding assay, but efficiently prevent thrombotic occlusion in the thrombosis models, is beyond the scope of this study, but probably involves a significant difference in local shear rates between these models. Indeed, thrombus formation in a vessel wall puncture with blood extravasation typically leads to a thrombus that grows intraluminally by no more than 50% [26] , which is insufficient to significantly increase local shear rates.
Effective inhibition of occlusive thrombus formation by antiplatelet NCs is directly determined by the amount of drug locally released from the NCs. It proved unfeasible to determine the release kinetics of eptifibatide at sites of developing thrombi. Thus, we monitored the functional consequence of local drug release: inhibition of thrombus formation. In our study, systemic concentrations of eptifibatide remained very low. The injection of 2.8 9 10
12 NCs (internal volume of 10.53 lL) with encapsulated eptifibatide at 350 lM in mice with a 2.0-mL blood bed volume would lead to a maximal systemic concentration of 0.453 lM. This value is based on the assumption that, maximally, 24.6% of encapsulated eptifibatide can be released in a shear-dependent manner, as shown in Fig. 1 . Importantly, this brief systemic eptifibatide concentration is 5.9-fold lower than current clinical loading doses in patients (180 lg kg
À1
; equating to 2.7 lM in the mouse). Despite these low systemic concentrations, the complete protection against vessel occlusion under the described conditions underscores the high efficiency of site-specific drug release by antiplatelet NCs.
Key limitations of these studies are that no viable endothelium was incorporated in the flow channels and abstract vessel geometries were used. Both features may have influenced the antiplatelet activity of the NCs. The in vivo thrombosis models feature severe vessel damage by ferric chloride or strong initiators of coagulation, which is non-physiologic, but nonetheless demonstrated the high efficacy of the eptifibatide NCs.
Although the shear-sensitive nature of lipid vesicles has been described [27] , this property has not been harnessed in the setting of antiplatelet therapy. We verified that the local delivery of antiplatelet drugs was a shear-dependent process by altering the membrane composition with Brij76, which is known to destabilize the lipid membrane and consequently decrease the shear stress threshold for membrane pore formation [16] . This tunability of shear stress sensitivity may prove to be beneficial when the antiplatelet NCs are investigated in larger animal models, where the vascular bed operates at different shear stress levels [17] .
The circulation half-life of PC-based liposomes is in the order of hours [28] , which, in its present setup, makes this approach an ideal therapy option in the setting of acute coronary syndrome (ACS) and PCI, where a rapidly reversible antiplatelet effect is highly desired [29, 30] . The short half-life of the antiplatelet NCs may allow for a reversible and potent therapeutic window with a lower bleeding risk, because it only inhibits platelets if and where vessel occlusion would occur.
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